Coherus Shakes Up Ranibizumab Competition With First Interchangeable US Biosimilar

Cimerli Version Approved By FDA For All Five Indications Of Lucentis Reference Product

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.